Seres Therapeutics Inc

NASDAQ:MCRB   3:59:52 PM EDT
6.51
+0.16 (+2.52%)
Products, Regulatory

Seres Therapeutics Enrolls 300 Subjects In Phase 3 Study Of Recurrent C. Difficile Infection Treatment

Published: 09/15/2021 11:21 GMT
Seres Therapeutics Inc (MCRB) - Seres Therapeutics Achieves Enrollment of 300 Subjects With Phase 3 Ecospor Iv Open-label Extension Study of Ser-109, a Potentially First-in-class Investigational Microbiome Therapeutic for Recurrent C. Difficile Infection.
Seres Therapeutics - Expects Completed Phase 3 Study Results and Pending Open-label Study Database to Finalize Bla Filing in Mid-2022.